Naijun Jiang

1 Introduction In cancer therapy, the development of drug resistance is a major factor limiting treatment efficacy. Both chemotherapeutic agents (such as cisplatin and paclitaxel) and targeted therapeutic drugs (such as EGFR inhibitors and BRAF inhibitors) can induce resistant phenotypes in cancer cells after prolonged use (1, 2). Drug resistance often stems from apoptosis evasion, but ferroptosis offers a tumor-specific alternative, particularly in malignancies with mesenchymal features (3).